Stringent patient selection improves outcomes in systemic light-chain amyloidosis after autologous stem cell transplantation in the upfront and relapsed setting.
作者信息
Venner Christopher P, Gillmore Julian D, Sachchithanantham Sajitha, Mahmood Shameem, Lane Thirusha, Foard Darren, Roussel Murielle, Rannigan Lisa, Gibbs Simon Dj, Pinney Jennifer H, Whelan Carol J, Lachmann Helen J, Hawkins Philip N, Wechalekar Ashutosh D
机构信息
National Amyloidosis Centre, University College London Medical School, UK Cross Cancer Institute, University of Alberta, Edmonton, Canada.
National Amyloidosis Centre, University College London Medical School, UK.
出版信息
Haematologica. 2014 Dec;99(12):e260-3. doi: 10.3324/haematol.2014.108191. Epub 2014 Sep 5.
Abstract
摘要
相似文献
1
Stringent patient selection improves outcomes in systemic light-chain amyloidosis after autologous stem cell transplantation in the upfront and relapsed setting.
Haematologica. 2014 Dec;99(12):e260-3. doi: 10.3324/haematol.2014.108191. Epub 2014 Sep 5.
2
Stem cell transplantation compared with melphalan plus dexamethasone in the treatment of immunoglobulin light-chain amyloidosis.
Cancer. 2016 Jul 15;122(14):2197-205. doi: 10.1002/cncr.30051. Epub 2016 May 3.
3
Outcomes and treatments of patients with immunoglobulin light chain amyloidosis who progress or relapse postautologous stem cell transplant.
Eur J Haematol. 2014 Jun;92(6):485-90. doi: 10.1111/ejh.12282. Epub 2014 Mar 2.
4
High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study.
Br J Haematol. 2004 Dec;127(5):543-51. doi: 10.1111/j.1365-2141.2004.05232.x.
5
The prognostic value of multiparameter flow cytometry minimal residual disease assessment in relapsed multiple myeloma.
Haematologica. 2015 Feb;100(2):e53-5. doi: 10.3324/haematol.2014.115162. Epub 2014 Nov 7.
6
Autologous stem cell transplant for immunoglobulin light chain amyloidosis: a status report.
Leuk Lymphoma. 2010 Dec;51(12):2181-7. doi: 10.3109/10428194.2010.524329. Epub 2010 Oct 20.
7
High dose therapy for light chain amyloidosis: can we reduce treatment related mortality further?
Leuk Lymphoma. 2008 Jan;49(1):4-5. doi: 10.1080/10428190701760078.
8
Extended follow up of high-dose melphalan and autologous stem cell transplantation after vincristine, doxorubicin, dexamethasone induction in amyloid light chain amyloidosis of the prospective phase II HOVON-41 study by the Dutch-Belgian Co-operative Trial Group for Hematology Oncology.
Haematologica. 2015 May;100(5):677-82. doi: 10.3324/haematol.2014.119198. Epub 2015 Feb 6.
9
Treatment patterns and outcome following initial relapse or refractory disease in patients with systemic light chain amyloidosis.
Am J Hematol. 2017 Jun;92(6):549-554. doi: 10.1002/ajh.24723. Epub 2017 Apr 26.
10
A second autologous hematopoietic cell transplantation is a safe and effective salvage therapy in select relapsed or refractory AL amyloidosis patients.
Bone Marrow Transplant. 2022 Feb;57(2):295-298. doi: 10.1038/s41409-021-01527-z. Epub 2021 Nov 20.
引用本文的文献
1
Cardiac Amyloidosis in Older Adults With a Focus on Frailty: JACC: Advances Expert Consensus.
JACC Adv. 2025 May 14;4(6 Pt 1):101784. doi: 10.1016/j.jacadv.2025.101784.
2
AL Amyloidosis: Current Treatment and Outcomes.
Adv Hematol. 2025 Mar 3;2025:7280805. doi: 10.1155/ah/7280805. eCollection 2025.
3
Autologous stem cell transplantation in AL amyloidosis: Muddy waters.
Blood Rev. 2024 Nov;68:101228. doi: 10.1016/j.blre.2024.101228. Epub 2024 Aug 10.
4
AL amyloidosis: untangling new therapies.
Hematology Am Soc Hematol Educ Program. 2021 Dec 10;2021(1):682-688. doi: 10.1182/hematology.2021000305.
5
Stem Cell Mobilization and Autologous Transplant for Immunoglobulin Light-Chain Amyloidosis.
Hematol Oncol Clin North Am. 2020 Dec;34(6):1133-1144. doi: 10.1016/j.hoc.2020.07.007. Epub 2020 Sep 12.
6
Deferred autologous stem cell transplantation in systemic AL amyloidosis.
Blood Cancer J. 2018 Nov 5;8(11):101. doi: 10.1038/s41408-018-0137-9.
7
Stem cell transplantation compared with melphalan plus dexamethasone in the treatment of immunoglobulin light-chain amyloidosis.
Cancer. 2016 Jul 15;122(14):2197-205. doi: 10.1002/cncr.30051. Epub 2016 May 3.
8
New Light Chain Amyloid Response Criteria Help Risk Stratification of Patients by Day 100 after Autologous Hematopoietic Cell Transplantation.
Biol Blood Marrow Transplant. 2016 Apr;22(4):768-770. doi: 10.1016/j.bbmt.2015.12.021. Epub 2015 Dec 29.
9
Update on treatment of light chain amyloidosis.
Haematologica. 2014 Feb;99(2):209-21. doi: 10.3324/haematol.2013.087619.
本文引用的文献
1
Lenalidomide and dexamethasone for systemic AL amyloidosis following prior treatment with thalidomide or bortezomib regimens.
Br J Haematol. 2014 Sep;166(6):842-8. doi: 10.1111/bjh.12973. Epub 2014 Jun 13.
2
High sensitivity cardiac troponin T in patients with immunoglobulin light chain amyloidosis.
Heart. 2014 Mar;100(5):383-8. doi: 10.1136/heartjnl-2013-304957. Epub 2014 Jan 8.
3
Autologous stem cell transplant is an effective therapy for carefully selected patients with AL amyloidosis: experience of a single institution.
Br J Haematol. 2014 Mar;164(5):722-8. doi: 10.1111/bjh.12673. Epub 2013 Nov 25.
4
Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach.
Haematologica. 2014 Apr;99(4):743-50. doi: 10.3324/haematol.2013.095463. Epub 2013 Nov 8.
5
New hematologic response criteria predict survival in patients with immunoglobulin light chain amyloidosis treated with high-dose melphalan and autologous stem-cell transplantation.
J Clin Oncol. 2013 Jul 20;31(21):2749-50. doi: 10.1200/JCO.2013.48.7736. Epub 2013 Jun 17.
6
Melphalan, lenalidomide and dexamethasone for the treatment of immunoglobulin light chain amyloidosis: results of a phase II trial.
Haematologica. 2013 May;98(5):789-92. doi: 10.3324/haematol.2012.075192. Epub 2012 Nov 9.
7
New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes.
J Clin Oncol. 2012 Dec 20;30(36):4541-9. doi: 10.1200/JCO.2011.37.7614. Epub 2012 Oct 22.
8
A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis.
Haematologica. 2013 Mar;98(3):433-6. doi: 10.3324/haematol.2012.073593. Epub 2012 Sep 14.
9
Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis.
Bone Marrow Transplant. 2013 Apr;48(4):557-61. doi: 10.1038/bmt.2012.170. Epub 2012 Sep 10.
10
Ten-year survival after autologous stem cell transplantation for immunoglobulin light chain amyloidosis.
Cancer. 2012 Dec 15;118(24):6105-9. doi: 10.1002/cncr.27660. Epub 2012 Jun 15.
Zotero 插件